These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 32085928)

  • 1. Are oral cefuroxime axetil, cefixime and cefditoren pivoxil adequate to treat uncomplicated acute pyelonephritis after switching from intravenous therapy? A pharmacokinetic/pharmacodynamic perspective.
    Rodríguez-Gascón A; Aguirre-Quiñonero A; Canut-Blasco A
    Enferm Infecc Microbiol Clin (Engl Ed); 2020; 38(7):306-311. PubMed ID: 32085928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil.
    Alvarez-Sala JL; Kardos P; Martínez-Beltrán J; Coronel P; Aguilar L
    Antimicrob Agents Chemother; 2006 May; 50(5):1762-7. PubMed ID: 16641447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics.
    Bulitta JB; Landersdorfer CB; Kinzig M; Holzgrabe U; Sorgel F
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3462-71. PubMed ID: 19528278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
    Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers.
    Nix DE; Symonds WT; Hyatt JM; Wilton JH; Teal MA; Reidenberg P; Affrime MB
    Pharmacotherapy; 1997; 17(1):121-5. PubMed ID: 9017772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the adequacy of the antimicrobial therapy of invasive Haemophilus influenzae infections: A pharmacokinetic/pharmacodynamic perspective.
    Ibar-Bariain M; Rodríguez-Gascón A; Isla A; Solinís MÁ; Canut-Blasco A
    Enferm Infecc Microbiol Clin (Engl Ed); 2021 Feb; 39(2):65-71. PubMed ID: 32636039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetic Model-Based Evaluation of Standard Dosing Regimens for Cefuroxime Used in Coronary Artery Bypass Graft Surgery with Cardiopulmonary Bypass.
    Alqahtani SA; Alsultan AS; Alqattan HM; Eldemerdash A; Albacker TB
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacteriological eradication of Streptococcus pneumoniae from patients with acute exacerbations of chronic bronchitis: cefuroxime axetil versus cefixime.
    Zuck P; Petitpretz P; Geslin P; Rio Y; Leblanc F
    Int J Clin Pract; 1999 Sep; 53(6):437-43. PubMed ID: 10622071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections.
    Bucko AD; Hunt BJ; Kidd SL; Hom R
    Clin Ther; 2002 Jul; 24(7):1134-47. PubMed ID: 12182257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of pharmacokinetic/pharmacodynamic analysis to evaluate the adequacy of antimicrobial therapy for pediatric acute otitis media in Spain before and after the introduction of the PCV7 vaccine.
    Ibar-Bariain M; Rodríguez-Gascón A; Isla A; Solinís MA; Canut-Blasco A
    Rev Esp Quimioter; 2019 Apr; 32(2):121-129. PubMed ID: 30727714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, randomized, double dummy, placebo-controlled trial of oral cefditoren pivoxil 400mg once daily as switch therapy after intravenous ceftriaxone in the treatment of acute pyelonephritis.
    Monmaturapoj T; Montakantikul P; Mootsikapun P; Tragulpiankit P
    Int J Infect Dis; 2012 Dec; 16(12):e843-9. PubMed ID: 22951426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum bactericidal activity of newer oral cephalosporins in healthy volunteers.
    Dan M; Poch F; Edelman A; Asherov J; Hafely H; Atzmon Y
    J Antimicrob Chemother; 1998 Apr; 41(4):485-8. PubMed ID: 9598780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefditoren pivoxil.
    Darkes MJ; Plosker GL
    Drugs; 2002; 62(2):319-36; discussion 337-8. PubMed ID: 11817976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of FCE 22891 compared with cefuroxime axetil and cefixime in pulmonary and subcutaneous infections in mice.
    Rossi R; Castellani P; Younes G; Della Bruna C
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():149-55. PubMed ID: 2732136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
    Lodise TP; Kinzig-Schippers M; Drusano GL; Loos U; Vogel F; Bulitta J; Hinder M; Sörgel F
    Antimicrob Agents Chemother; 2008 Jun; 52(6):1945-51. PubMed ID: 17485507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria.
    Asín E; Isla A; Canut A; Rodríguez Gascón A
    Int J Antimicrob Agents; 2012 Oct; 40(4):313-22. PubMed ID: 22921422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of cefuroxime for women with community-onset acute pyelonephritis caused by cefuroxime-susceptible or -resistant Escherichia coli.
    Chang UI; Kim HW; Wie SH
    Korean J Intern Med; 2016 Jan; 31(1):145-55. PubMed ID: 26767868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefuroxime axetil: an updated review of its use in the management of bacterial infections.
    Scott LJ; Ormrod D; Goa KL
    Drugs; 2001; 61(10):1455-500. PubMed ID: 11558834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis.
    Wu J; Wu H; Wang Y; Chen Y; Guo B; Cao G; Wu X; Yu J; Wu J; Zhu D; Guo Y; Yuan H; Hu F; Zhang J
    Clin Ther; 2019 Jun; 41(6):1164-1174.e4. PubMed ID: 31126694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.